Status:
COMPLETED
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergic Rhinoconjunctivitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to assess the tolerability of AVANZ.
Detailed Description
To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense. The frequency of patients with adverse reactions will be the study primary endpoint.
Eligibility Criteria
Inclusion
- History of grass pollen rhinoconjunctivitis
- Positive SPT to Phleum pratense
- Positive specific IgE against Phleum pratense
Exclusion
- Uncontrolled severe asthma
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT01454531
Start Date
June 1 2011
End Date
April 1 2012
Last Update
March 6 2015
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Basurto
Bilbao, Bilbao, Spain, 48013
2
Fundación Jiménez Diaz
Madrid, Madrid, Spain, 28025
3
Hospital Infanta Elena
Madrid, Madrid, Spain, 28342
4
Hospital Universitari Politecnic La Fe
Valencia, Valencia, Spain, 46026